Abstract:B-precursor acute lymphoblastic leukemia (B-ALL) is the leading cause of cancer-related death in young people and commonly has poor outcomes in adults. Dysregulation of cytokine signaling frequently occur in high-risk ALL and correlates with poor prognosis. Molecular insight into activation of oncogenic cytokine signaling comes from the recent discovery of loss-of-function mutations in the adaptor protein LNK (or SH2B3) and constitutive active JAK2 mutations in Ph-like pediatric B-ALL, the subtype that lacks Philadelphia (Ph) chromosome translocation, yet displays a similar activated kinase signature to Ph+ ALL. While clearly established at the genetic level, mechanisms by which LNK mutation impacts ALL initiation or progression have not been established. Here we show that LNK synergizes with TP53 in suppressing B-ALL development in mice. Lnk-/-Tp53-/- B-ALLs are highly aggressive with 100% penetrance. More importantly, Lnk-/-Tp53-/- B blasts specifically exhibit gene signatures of human Ph-like ALL. Mechanistically, we demonstrate that B progenitors from preleukemic Lnk-/-Tp53-/- mice are hypersensitive to IL-7 and display marked self-renewal ability in vitro and in vivo. Using a novel phosphoflow strategy that enables interrogation of early transformative signaling events in B progenitors at different stages, we find that Lnk deficiency confers a heightened sensitivity to IL-7 in activating pStat5 in pro B progenitors. Furthermore, Lnk-/-Tp53-/- B blasts show constitutive activation of pAkt and pS6, but still depend on IL-7 for activation of Stat5. Moreover, Lnk-/-Tp53-/- B blasts are less sensitive to JAK inhibitors than normal B progenitors, consistent with the inability of JAK inhibition to eradicate B-ALL in humans. High-risk B-ALLs that show genetic mutations in cytokine dependent pathways and elevated cytokine signaling have poor survival rates. Our research focuses on a novel B-ALL mouse model to decipher mechanisms underlying high-risk ALL, and will enhance our understanding of this incurable disease and provide novel insights into therapeutic strategies. B-precursor acute lymphoblastic leukemia (B-ALL) is the leading cause of cancer-related death in young people and commonly has poor outcomes in adults. Dysregulation of cytokine signaling frequently occur in high-risk ALL and correlates with poor prognosis. Molecular insight into activation of oncogenic cytokine signaling comes from the recent discovery of loss-of-function mutations in the adaptor protein LNK (or SH2B3) and constitutive active JAK2 mutations in Ph-like pediatric B-ALL, the subtype that lacks Philadelphia (Ph) chromosome translocation, yet displays a similar activated kinase signature to Ph+ ALL. While clearly established at the genetic level, mechanisms by which LNK mutation impacts ALL initiation or progression have not been established. Here we show that LNK synergizes with TP53 in suppressing B-ALL development in mice. Lnk-/-Tp53-/- B-ALLs are highly aggressive with 100% penetrance. More importantly, Lnk-/-Tp53-/- B blasts specifically exhibit gene signatures of human Ph-like ALL. Mechanistically, we demonstrate that B progenitors from preleukemic Lnk-/-Tp53-/- mice are hypersensitive to IL-7 and display marked self-renewal ability in vitro and in vivo. Using a novel phosphoflow strategy that enables interrogation of early transformative signaling events in B progenitors at different stages, we find that Lnk deficiency confers a heightened sensitivity to IL-7 in activating pStat5 in pro B progenitors. Furthermore, Lnk-/-Tp53-/- B blasts show constitutive activation of pAkt and pS6, but still depend on IL-7 for activation of Stat5. Moreover, Lnk-/-Tp53-/- B blasts are less sensitive to JAK inhibitors than normal B progenitors, consistent with the inability of JAK inhibition to eradicate B-ALL in humans. High-risk B-ALLs that show genetic mutations in cytokine dependent pathways and elevated cytokine signaling have poor survival rates. Our research focuses on a novel B-ALL mouse model to decipher mechanisms underlying high-risk ALL, and will enhance our understanding of this incurable disease and provide novel insights into therapeutic strategies.

The Role and Mechanism of PTPN21 Isoforms in Acute Lymphoblastic Leukemia Escaping NK Cell Killing

PTPN21 Plays a Role in Occurrence and Relapse of Acute Lymphoblastic Leukemia by Promoting the Proliferation of Acute Lymphoblastic Leukemic Cells Via Activating MAPK Signal Pathways

PTPN21‐CDSlong Isoform Inhibits the Response of Acute Lymphoblastic Leukemia Cells to NK‐mediated Lysis Via the KIR/HLA‐I Axis

Prognostic Significance of the Tumor Suppressor Protein P53 Gene in Childhood Acute Lymphoblastic Leukemia.

Overexpression of PTPN21 Promotes Proliferation of EGF-stimulated Acute Lymphoblastic Leukemia Cells Via the MAPK Signaling Pathways

Spectrum and Clinical Features of Gene Mutations in Chinese Pediatric Acute Lymphoblastic Leukemia

A novel tumor suppressor sh2b3 in acute lymphoblastic leukemia

Ras Pathway Mutation Feature in the Same Individuals at Diagnosis and Relapse of Childhood Acute Lymphoblastic Leukemia

Janus Kinase Inhibition by Ruxolitinib Combined with Nilotinib Has Superior Anti-Leukemia Propagating Cells Effect in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Effects of NRAS Mutations on Leukemogenesis and Targeting of Children With Acute Lymphoblastic Leukemia

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia

Pan-cancer analysis revealing that PTPN2 is an indicator of risk stratification for acute myeloid leukemia

The Experimental Study on Predicting the Relapse of Acute Lymphoblastic Leukemia

Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic cell transplantation.

Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond.

Therapy-induced Mutations Drive the Genomic Landscape of Relapsed Acute Lymphoblastic Leukemia.

LncRNA PPM1A-AS Regulate Tumor Development Through Multiple Signal Pathways in T-Cell Acute Lymphoblastic Leukemia

Data from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Abstract 624: Ptpn1 deficiency collaborates with a NUP98::HOXD13 fusion gene to generate B cell precursor acute lymphoblastic leukemia

The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China

Gene Expression Prognostic of Early Relapse Risk in Low‐risk B‐cell Acute Lymphoblastic Leukaemia in Children